Source:http://linkedlifedata.com/resource/pubmed/id/18940269
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2009-5-4
|
| pubmed:abstractText |
We sought to determine whether quantitative assessment of anti-cytomegalovirus (CMV) antibodies could be useful to identify patients at risk of cytomegalovirus (CMV) disease after heart transplantation (HT). 75 patients who underwent HT at a single health care center were prospectively studied. Induction therapy included 2 doses of daclizumab and maintenance tacrolimus (n=42) or cyclosporine (n=29), mycophenolate mofetil and prednisone. All patients received prophylaxis with gancyclovir or valganciclovir. Anti-CMV intravenous immunoglobulin (CMV-IG) was added in high risk patients (CMV D+/R- serostatus). Serial determinations of anti-CMV antibodies, immunoglobulins (IgG, IgA, IgM) and IgG-subclasses were analysed. CMV infection was based on detection of the virus by antigenemia. CMV disease consisted of detection of signs or symptoms attributable to this microorganism. Ten patients (13.3%) developed CMV disease. Mean time of development of CMV disease was 3.4+/-1.6 months. In Cox regression analysis, patients with low baseline anti-CMV titers (<4.26 natural logarithm of titer, RH: 8.1, 95%CI: 1.93-34.1, p=0.004) and recipients with 1-month post-HT IgG hypogammaglobulinemia (IgG<500 mg/dl, RH: 4.49, 95%CI: 1.26-15.94, p=0.02) were at higher risk of having CMV disease. Despite use of prophylactic CMV-IG, D+/R- patients showed significantly lower titers of anti-CMV antibodies at 7 d, 30 d and 90 d post HT as compared with HT recipients without infections. Four out of 6 of these patients developed late CMV disease. Monitoring of specific anti-CMV antibodies on the bedside warrants further evaluation as a potential tool to identify heart transplant recipients at higher risk of CMV disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1878-1705
|
| pubmed:author |
pubmed-author:AlonsoRobertoR,
pubmed-author:CarboneJavierJ,
pubmed-author:Fernandez-CruzEduardoE,
pubmed-author:Fernandez-YañezJuanJ,
pubmed-author:GallegoAntonioA,
pubmed-author:LanioNallibeN,
pubmed-author:NavarroJoaquinJ,
pubmed-author:PalomoJesusJ,
pubmed-author:Rodríguez-HernándezCesarC,
pubmed-author:Rodriguez-MolinaJuanJ,
pubmed-author:RuizManuelM,
pubmed-author:SarmientoElizabethE
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
649-52
|
| pubmed:meshHeading |
pubmed-meshheading:18940269-Adult,
pubmed-meshheading:18940269-Antibodies, Viral,
pubmed-meshheading:18940269-Antiviral Agents,
pubmed-meshheading:18940269-Cohort Studies,
pubmed-meshheading:18940269-Cytomegalovirus,
pubmed-meshheading:18940269-Cytomegalovirus Infections,
pubmed-meshheading:18940269-Female,
pubmed-meshheading:18940269-Follow-Up Studies,
pubmed-meshheading:18940269-Heart Transplantation,
pubmed-meshheading:18940269-Humans,
pubmed-meshheading:18940269-Immunoglobulins,
pubmed-meshheading:18940269-Immunoglobulins, Intravenous,
pubmed-meshheading:18940269-Male,
pubmed-meshheading:18940269-Middle Aged,
pubmed-meshheading:18940269-Monitoring, Immunologic,
pubmed-meshheading:18940269-Proportional Hazards Models,
pubmed-meshheading:18940269-Prospective Studies,
pubmed-meshheading:18940269-Regression Analysis
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
|
| pubmed:affiliation |
Transplant Immunology Group, Immunology Department, University Hospital Gregorio Marañon, Madrid, Spain. esarmiento.hgugm@salud.madrid.org
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|